ESMO 2025 bladder cancer highlights include results from KEYNOTE-905/EV-303, RC48-C016, and IMvigor011 studies.

Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure.

Barrett also reported JELMYTO net product revenue of $25.7 million for the quarter, citing a 13% increase in underlying demand revenue over the same period in 2024, and announced continued pipeline ...

The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...

The addition of durvalumab to bacillus Calmette-Guérin therapy significantly extended DFS for patients with high-risk non-muscle-invasive bladder cancer, according to results of a randomized phase 3 ...

Month Follow-up Safety and Efficacy Data in NMIBC FDA feedback supports 2 potential registrational trials – 1) a registrational trial in 2nd line refractory BCG-unresponsive NMIBC, and 2) a randomized ...

For Cohorts A and B, intravesical cretostimogene will be instilled in combination with DDM, an excipient that enhances adenoviral delivery, for six weekly doses during the induction phase, followed by ...

Cretostimogene grenadenorepvec, an oncolytic immunotherapy, selectively replicates in and lyses cancer cells with Rb-E2F pathway alterations, releasing antigens that initiate antitumor immune ...

"I'm very excited to bring this therapy to our patients in the Philadelphia area and to be able to offer it at MidLantic," says David Cahn, DO, MBS, FACOS. "For me and the patients, [nadofaragene ...